Two new real-world evidence studies exploring the efficacy of two treatments for COVID-19 have been published in the British Medical Journal (BMJ). The first study investigated real-world data (RWD) from fully vaccinated high-risk adult patients in England. Those taking sotrovimab had better COVID-19 outcomes than people taking molnupiravir, most notably a 46% reduction in severe COVID-19.
According to Medical Xpress, “The second is a randomized controlled trial involving 787 patients (778 from India and nine from Australia) with an average age of 49 years, admitted to hospital from May 2020 to November 2021. Included patients had predominantly mild disease, although the researchers aimed to recruit patients at risk of severe COVID.”
To read more, click here.
(Source: November 16th, 2022)